Navigation Links
BioMarin to Present at the William Blair Growth Stock Conference
Date:6/3/2009

NOVATO, Calif., June 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Wednesday, June 10, 2009 at 12:00 p.m. CT.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), N
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
10. BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. BioMarin Supports Observance of Rare Disease Day February 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Portland, Oregon (PRWEB) October 20, 2014 Succeed ... 16% of local companies who participated in the Every ... Walk! is a public awareness project that encourages workers to ... the Summer Step 10,000 Program, which concluded at the end ... wide variety of cities and metro areas. Participating companies ...
(Date:10/20/2014)... 20, 2014 Unveiled at the Sept. 18 ... Scorecard conservatively estimates member hospital ROI on membership dues at ... The Center provides $12.50 in value to member hospitals. The ... – Member Dues)/Member Dues. , “This is the first ... and we think the methodology is really sound,” said ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... The ability of the commonly used stimulant methylphenidate (Ritalin) ... both to the inhaled gas isoflurane, as previously reported, ... the same Massachusetts General Hospital (MGH) research team that ... propofol in the May issue of Anesthesiology, ...
... Reporter , THURSDAY, April 5 (HealthDay News) -- Exposure ... eaten by U.S. consumers is linked to shorter pregnancies ... are known as organophosphates, which kill insects by disrupting ... poisons during World War II, they can disrupt human ...
... Reporter , THURSDAY, April 5 (HealthDay News) -- Developing stem ... tumors has been one of the biggest challenges for stem ... of Philadelphia have generated a new line of stem cells ... destined for the digestive system or possibly the lungs. ...
... children undergoing early-stage surgery for single-ventricle heart defects, ... neurodevelopmental outcomes at 14 months of age. Instead, ... general medical morbidity during the child,s first year ... left-heart syndrome (HLHS) and related single-ventricle defects have ...
... ORANGE, N.J. April 4, 2012. John Whyte, MD, PhD, is ... Award for Excellence in Research and Education in the Field ... honored at the Foundation,s Board of Trustees dinner in West ... grant for Dr. Whyte,s research activities. Dr. ...
... Researchers reporting in the April Cell Stem Cell , ... leukemia stem cells in their tracks. The advance in mice ... chronic myeloid leukemia (CML) for good. That,s in contrast ... imatinib (aka Gleevec) today, who often go into remission only ...
Cached Medicine News:Health News:Recovery from propofol anesthesia may be sped by use of common stimulant 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 3Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 4Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 2Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 3Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 4Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 2Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 3Health News:Kessler Foundation names Dr. John Whyte recipient of Foundation's 2nd Annual DeLisa Award 2Health News:To prevent leukemia's dreaded return, go for the stem cells 2
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
(Date:10/18/2014)... WASHINGTON , Oct. 18, 2014  In ... Human Rights Campaign (HRC), the nation,s largest lesbian, ... explicitly endorsed the use of Truvada for Pre-Exposure ... health tool used to prevent the spread of ... is the only brand name anti-HIV drug combination ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... Johnson Pharmaceutical,Research & Development, L.L.C. (J&JPRD), today ... doripenem for injection), a,carbapenem antibiotic, was found ... certain,strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases,(ESBLs) than ... a large group of bacteria that can ...
... Data Shows Long-term Improvements in Productivity, Quality of ... American College ... Oct. 27 5:00 AM PST -- UCB announced,today ... pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor),- ...
Cached Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10
... is the most advanced means of documenting ... management system that acquires extremely high quality ... can be captured directly from slit lamps ... well as any other ophthalmic device with ...
... device that replaces the old technology, the ... by bringing virtually unlimited charts to the ... are at the practitioners finger tips. The ... charts, optotypes, associated vision tests and fixation ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
... Two mirrored surfaces, which each incline ... front surface, have been cut into the ... it possible to examine the opposite iridocorneal ... expanse and form of the angle of ...
Medicine Products: